Mathias Haag

Circulating metabolite signatures indicate differential gut-liver crosstalk in lean and obese MASLD

First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure

Circulating Biomarkers Instead of Genotyping to Establish Metabolizer Phenotypes

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

Nicotinamide‐N‐methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma

CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL

Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study

Quantification of Signaling Lipids by Nano-Electrospray Ionization Tandem Mass Spectrometry (Nano-ESI MS/MS)